CLINICAL TRIALS PROFILE FOR PROTONIX
✉ Email this page to a colleague
All Clinical Trials for Protonix
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00133770 ↗ | Intravenous (IV) Pantoprazole in Erosive Esophagitis | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 | 2004-07-01 | The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis. |
| NCT00133770 ↗ | Intravenous (IV) Pantoprazole in Erosive Esophagitis | Completed | Emory University | Phase 4 | 2004-07-01 | The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis. |
| NCT00206050 ↗ | Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po | Completed | AstraZeneca | Phase 4 | 2004-09-01 | This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection). |
| NCT00625274 ↗ | A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients | Completed | AstraZeneca | Phase 4 | 2004-06-01 | This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs). |
| NCT00674245 ↗ | Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD. | Completed | Southern Arizona VA Health Care System | Phase 2/Phase 3 | 2008-04-01 | The purpose of this research study is to determine if treatment with pantoprazole 40 mg daily versus a placebo improves sleep quality in patients with gastroesophageal reflux disease (GERD). Another purpose is to determine if treatment with pantoprazole 40 mg once daily versus a placebo improves sleep outcomes in patients with gastroesophageal reflux disease using spectral analysis of sleep electroencephalogram (EEG). |
| NCT00699361 ↗ | Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure | Withdrawn | Johann Wolfgang Goethe University Hospital | Phase 3 | 2008-08-01 | Recently literature revealed facts, that show H+/K+ ATPase expression is not limited tot he stomach. H+/K+ ATPase was also found in smooth muscle cells and in other tissues (McCabe, R.D. et al., Am J Physiol. 1992). For myocard a localisation is only proven for rats yet (Beisvag, V. et al., Acta Physiol Scand. 2003). Moreover biochemical hints lead us to a highly probability of a myocardial H+/K+ ATPase (Nagashima, R. et al., Jpn Heart J. 1999). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Protonix
Condition Name
Clinical Trial Locations for Protonix
Trials by Country
Clinical Trial Progress for Protonix
Clinical Trial Phase
Clinical Trial Sponsors for Protonix
Sponsor Name
